Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir and Lamivudine PK Interaction Study
NCT06811246Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of islatravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Peripheral blood mononuclear cell (PBMC) Concentration at 168 hours of islatravir-triphosphate (ISL-TP), PBMC Concentration at 24 Hours of ISL-TP and 5 more. Started Feb 2024; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06811246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811246.